Combination therapy

Delve into the world of Combination therapy in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Combination therapy to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

China's NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products
Policy / Regulatory

China’s NMPA Unveils Draft Regulations on Radiopharmaceuticals – Public Consultation Open Through October 20 With Priority Review for Urgent‑Demand Products

China's National Medical Products Administration (NMPA) released the draft Regulations on the Administration of Radiopharmaceuticals and opened a public comment period through October 20. The draft establishes a dedicated regulatory…

Merck Licenses SciBrunch's Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

Merck Licenses SciBrunch’s Oral KRAS G12D Inhibitor SPR2015 in Up to USD 2.13 Billion Exclusive Global Deal

FDA Approves Eli Lilly's Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

FDA Approves Eli Lilly’s Olumiant for Pediatric Patients Aged 12 and Older With Severe Alopecia Areata

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi

CompanyDeals

Brii Biosciences Publishes Positive Phase II Results for HBV Treatment

CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study

CompanyDrug

RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study

CompanyDrug

JS InnoPharm’s US Subsidiary Initiates Phase I Trial for AURKA Inhibitor VIC-1911

CompanyDrug

Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC

CompanyDrug

Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy

CompanyDrug

Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study

Show More